Abstract-The concept that hepatic cholesteryl ester (CE) mass and the rate of cholesterol esterification regulate hepatocyte assembly and secretion of apoB-containing lipoproteins remains controversial. The present study was carried out in HepG2 cells to correlate the rate of cholesterol esterification and CE mass with apoB secretion by CI-1011, an acyl CoA:cholesterol acyltransferase (ACAT) inhibitor that is known to decrease apoB secretion, in vivo, in miniature pigs. HepG2 cells were incubated with CI-1011 (10 nmol/L, 1 mol/L, and 10 mol/L) for 24 hours. ApoB secretion into media was decreased by 25%, 27%, and 43%, respectively (PϽ0.0012). CI-1011 (10 mol/L) inhibited HepG2 cell ACAT activity by 79% (PϽ0.002) and cellular CE mass by 32% (PϽ0.05). In contrast, another ACAT inhibitor, DuP 128 (10 mol/L), decreased cellular ACAT activity and CE mass by 85% (PϽ0.002) and 42% (Pϭ0.01), respectively, but had no effect on apoB secretion into media. To characterize the reduction in apoB secretion by CI-1011, pulse-chase experiments were performed and analyzed by multicompartmental modelling using SAAM II. CI-1011 did not affect the synthesis of apoB or albumin. However, apoB secretion into the media was decreased by 42% (Pϭ0.019). Intracellular apoB degradation increased proportionately (Pϭ0.019). A poB100, synthesized in the liver, is an essential structural component of VLDL and its metabolic products, IDL and LDL. 1,2 ApoB is required for the intracellular assembly and secretion of these lipoproteins, and serves as a ligand for LDL receptor-mediated clearance of these particles from the plasma. 3 Hepatic overproduction of apoB-containing lipoproteins is a major risk factor for atherosclerosis. Therefore, studies designed to understand the processes regulating apoB assembly and secretion from hepatocytes are important. The production of these lipoproteins is complex and requires the coordinated synthesis and assembly of apoB, triglyceride (TG), free and esterified cholesterol (FC; cholesteryl ester, CE), phospholipids (PLs), and other components. Although considerable progress has been made in understanding these processes, many questions remain unresolved.
A poB100, synthesized in the liver, is an essential structural component of VLDL and its metabolic products, IDL and LDL. 1, 2 ApoB is required for the intracellular assembly and secretion of these lipoproteins, and serves as a ligand for LDL receptor-mediated clearance of these particles from the plasma. 3 Hepatic overproduction of apoB-containing lipoproteins is a major risk factor for atherosclerosis. Therefore, studies designed to understand the processes regulating apoB assembly and secretion from hepatocytes are important. The production of these lipoproteins is complex and requires the coordinated synthesis and assembly of apoB, triglyceride (TG), free and esterified cholesterol (FC; cholesteryl ester, CE), phospholipids (PLs), and other components. Although considerable progress has been made in understanding these processes, many questions remain unresolved.
ApoB is thought to be regulated primarily at posttranscriptional levels. The rates of apoB translocation across the endoplasmic reticulum (ER) membrane and intracellular degradation are believed to regulate the amount of apoBcontaining lipoproteins secreted from the liver. 4, 5 Therefore, the secretion rate of apoB results from the proportion of newly synthesized apoB molecules that associate with lipid and move through the secretory pathway, versus the proportion that are degraded within the cell shortly after, or during, their synthesis. Although hepatic regulation of apoB secretion is generally considered to occur posttranslationally, transcriptional regulation may also play a minor role. Increased delivery of 25-hydroxycholesterol 6 or VLDL 7 to cultured hepatocytes has been shown to affect mRNA levels and secretion efficiency of apoB.
Several factors have been suggested to play key roles in the translational and posttranslational regulation of apoB secretion, including amino acid concentration, hormonal environment, and hepatic lipid availability and composition. 8 -11 Of these factors, lipid availability has recently received considerable attention. The importance of hepatic triglyceride for apoB secretion has been well documented. 7, 8, [12] [13] [14] [15] Increased triglyceride synthesis has been shown to regulate apoB posttranscriptionally, by reducing the proportion of apoB degraded intracellularly, thus increasing secretion. 7, 12 Reduced availability of PL, the major surface component of VLDL, has also been shown to decrease VLDL secretion from rat hepatocytes. 16 The role of hepatic CE in the assembly and secretion of apoB-containing lipoproteins remains controversial. The regulation of apoB secretion by the rate of cholesterol synthesis, esterification, and/or the mass of CE, has been documented in vitro 6, [17] [18] [19] [20] [21] and in vivo. [22] [23] [24] [25] In contrast, several studies argue against the regulation of apoB by CE availability. 8, [13] [14] [15] 26 For example, Wu et al 14 have shown that apoB secretion from HepG2 cells was unaffected by either long-or short-term changes in cellular CE content. Similar conclusions were reported by Furukawa et al 13 and Sato et al 26 in studies involving the inhibition of cholesterol synthesis in HepG2 cells. One possible explanation for these discrepancies may be the comparison of apoB secretion in relation to CE synthesis rates rather than cellular CE mass. Kohen Avramoglu et al 20 have shown that not only newly synthesized, but also preformed CE, stimulates the secretion of apoB-containing lipoproteins. Additional discrepancies may arise from the choice of cell model used, as hepatoma cell lines and primary hepatocytes have been shown to differ in their response to modulators of FC and CE biosynthesis. 21, 27 Nevertheless, the role of CE in the assembly and secretion of apoB-containing lipoproteins remains unresolved.
The present study was designed to further investigate the regulation of apoB secretion by inhibition of cholesterol esterification, using 2 specific acyl CoA:cholesterol acyltransferase (ACAT) inhibitors, CI-1011 and DuP 128. Studies in chow-fed rats and rabbits fed a cholesterol-free casein diet revealed that CI-1011 is more effective in reducing plasma total cholesterol (TC) levels than equivalent doses of DuP 128. 28 Previous in vivo apoB kinetic studies from this laboratory have shown that DuP 128, a potent noncompetitive inhibitor of ACAT, significantly inhibited hepatic ACAT when administered to pigs intravenously. 23, 29 This was associated with a significant decrease in the VLDL apoB secretion into plasma, but had no effect on LDL apoB production. A recently developed ACAT inhibitor, CI-1011, has marked lipid and apoB lowering ability in vivo, 30 -32 and displays ACAT inhibitory activity in vitro. 28 In contrast to DuP 128, oral administration of CI-1011 decreased both VLDL and LDL apoB production rates in apoB kinetic studies performed in pigs. 33 These 2 inhibitors differ in structure, lipid solubility, and 50% inhibitory concentration (IC 50 ), raising the possibility that the mechanism(s) by which these inhibitors regulate apoB secretion may differ. The mechanism of CI-1011 action on apoB secretion in vitro has not been previously studied. Therefore, in the present study, the ACAT inhibitors CI-1011 and DuP 128 were used as probes to investigate the role of cholesterol esterification and CE mass, in the regulation of apoB secretion from HepG2 cells. Specifically, this study was conducted (1) to determine if the in vivo differences in apoB secretion, as stated above, would be revealed in HepG2 cells (the most widely used cell model for apoB secretion to date), thus allowing us to investigate the mechanisms for these differences, and (2) to examine whether the effect of ACAT inhibition on apoB secretion is associated with changes in apoB intracellular degradation. We explored the kinetics of cellular apoB metabolism using the novel approach of multicompartmental modelling, using SAAM II to analyze pulse-chase studies. The results of this study demonstrated that both ACAT inhibitors decreased cellular CE mass and cholesterol esterification; however, only CI-1011 decreased apoB secretion from HepG2 cells. These findings reveal potentially novel mechanisms regulating apoB secretion in HepG2 cells by CI-1011 that may be independent of its ability to inhibit cholesterol esterification.
Methods

Cell Culture
HepG2 cells were obtained from the American Type Culture Collection (ATCC) and grown on 100 mm culture dishes (Falcon Scientific) as described previously. 34 For experiments, HepG2 cells were plated in either 100-mm culture dishes for RNA isolation, or in 6-well (35-mm) culture plates (Falcon Scientific) for all other experiments. The cells were washed with citrate saline (15 mmol/L sodium citrate, 0.13 mol/L potassium chloride, pH 7.4) and the media replaced with MEM containing 5% human lipoprotein deficient serum (LPDS). The appropriate concentrations of ACAT inhibitors, solubilized in DMSO, were added to the dishes. The ACAT inhibitor CI-1011 was provided by Parke-Davis Pharmaceutical Research and DuP 128 was provided by DuPont Merck Pharmaceutical Co. Experimental DMSO concentrations did not exceed 0.5% and all incubation media were adjusted for the same DMSO concentration. In some experiments, 0.8 mmol/L oleic acid, complexed to fatty acid free BSA in a molar ratio of 5:1 was added to the cells when the inhibitors were added.
Unless otherwise stated, the effect of ACAT inhibition was studied over a 24-hour period. After the incubation period, the medium was collected from the 35-mm dishes and centrifuged at 2500 rpm (IEC Centra-8R centrifuge) for 10 minutes to remove detached cells and debris. The supernatant was immediately stored at Ϫ80°C for measurement of apoB100 concentrations. The cells were washed 2 times with 1 mL of buffer B (0.15 mol/L NaCl, 50 mmol/L Tris, pH 7.4, 0.2% BSA) and then washed 2 times in the same buffer without BSA. Cellular lipids were extracted with 1 mL of hexaneisopropanol, 3:2 (vol/vol). After 30 minutes the extracts were removed and the cells extracted with an additional 1 mL of hexane-isopropanol, 3:2 (vol/vol). The 2 extracts were pooled for analysis. The soluble cell protein was dissolved in 2 mL of 0.1 mol/L NaOH and collected. Cell protein content was analyzed by a modification of the Lowry method. 35 
ApoB Mass Quantitation
ApoB concentrations in the medium were measured by ELISA. In the ELISA, monoclonal human apoB antibody (Calbiochem) was used as the capture antibody, and an affinity purified polyclonal apoB antibody conjugated to peroxidase (The Binding Site) was used for detection. O-phenylenediamine dihydrochloride (Sigma-Aldrich) was used as substrate for color development, and the absorbance at 450 nm was determined using a Vmax Kinetic 96 multi-well microplate reader (Molecular Devices). A purified human LDL standard (dϭ1.030 to 1.050 g/mL) was used to calibrate the assay. Media samples were diluted 10-fold for analysis. ApoB mass results are reported as g per mg cell protein.
Lipid Mass Quantitation
Cellular TG, FC, and TC were quantitated by a modification of the method of Carr et al, 36 using enzymatic reagents from Boehringer Mannheim and a Vmax Kinetic 96 multi-well microplate reader. The extracted lipids from each sample were evaporated to dryness under N 2 , resuspended in 2.4 mL of a chloroform/Triton X-100 mixture (0.5% Triton X-100 vol/vol), and the solvent evaporated again under N 2 . The samples were resolubilized in 600 L of deionized H 2 O (final concentration, 2% Triton X-100). Cellular lipids were then analyzed as described previously. 37 For the determination of triglyceride mass, samples were diluted 2:5 (vol/vol) with a 2% Triton X-100 (in deionized H 2 O, vol/vol) solution, and analyzed as de-scribed. 37 Cellular lipid results are reported as g of cellular lipid (CE, TG, or FC) per mg cell protein.
Lipid Synthesis and Secretion
The incorporation of [1- 14 C] oleic acid (Amersham) into cellular CE and TG was determined by a modification of the methods described previously. 34 Each dish received 0.08 Ci of [1- 14 C] oleic acid (50 mCi/mmol), complexed with fatty acid-free BSA. The incorporation of [1- 14 C] acetic acid (Amersham) into cellular CE, TC, and PL was determined by the addition of 0.5 Ci acetic acid (57 mCi/mmol) per well. Incubations were carried out for 5 hours, either immediately after the addition of the desired inhibitors, or after a 19-hour preincubation with the inhibitors. The incubations were terminated by washing the cells 3 times with buffer B without BSA. The lipids were extracted in situ as described above. The extracted lipids from cells incubated with [1- 14 C] acetic acid were divided into 2 equal fractions. One fraction was saponified as described previously, 34 and the determination of [1- 14 C] acetic acid incorporation into TC was determined after thin layer chromatography (TLC) as described below. The other fraction, and the lipid extract from the [1- 14 C] oleic acid incorporation studies, were not saponified; radioactivity incorporated into the various lipid fractions was determined after TLC. 34 The silica gel was scraped into vials containing 8 mL scintillation fluid (Aquasol, Packard) for counting (Beckman LS 3801 liquid scintillation counter). The determination of radiolabeled CE, TG, and PL secreted into the media was performed, as described above, after a 24-hour incubation rather than a 5-hour incubation. The media was removed after the 24-hour incubation and the lipids recovered by the method of Folch et al. 38 The extracted lipids were separated by TLC and analyzed as described above.
Analysis of Lipoprotein Fractions
The distribution of secreted apoB into lipoproteins with the density of VLDL (dϽ1.006 g/mL), IDL (dϭ1.006 to 1.019 g/mL), and LDL (dϭ1.019 to 1.063 g/mL) was determined after the incubation of cells with 50 Ci (150 Ci/mmol) L- [4,5- 3 H] leucine (Amersham) for 24 hours. The media was removed after the incubation and mixed with 4 mL normal human plasma. VLDL, IDL, and LDL fractions were isolated by ultracentrifugation, as described previously. 39 ApoB was isolated from each lipoprotein fraction by isopropanol precipitation 39 and analyzed by scintillation counting. This precipitation method is specific for apoB, as described by Egusa et al. 40 
Pulse-Chase Experiments
Cells were preincubated with CI-1011 (10 mol/L) or DMSO (control) for 24 hours before metabolic labeling. The cells were washed 2 times with PBS, warmed to 37°C and incubated with methionine-free MEM (ICN) for 20 minutes. Cells were then pulsed for 10 minutes with 100 Ci/mL Tran [ To assess the uptake of newly secreted apoB-containing lipoproteins, untreated cells were pulsed with Tran [
35 S] label for 10 minutes and chased for 60 minutes as outlined above. This media, containing [ 35 S] apoB-lipoproteins, was collected and placed on other cells that had been pretreated with CI-1011 (10 mol/L) or DMSO alone (control), for 24 hours. After the cells were incubated in the labeled media for 60 minutes, the media were collected, and apoB immunoprecipitated as outlined below.
Immunoprecipitation of cell extracts and media was carried out by a method similar to that described by Adeli, 41 with some modification. Briefly, aliquots of cell extracts and media were incubated with 10 L preimmune rabbit serum for 1 hour. Insoluble Protein A (30 L, Staphylococcus aureus suspension; Sigma) was added to each sample and incubated for 1 hour. Each tube was centrifuged at 14 000 rpm for 5 minutes and the supernatant was transferred to a tube containing 5 L of anti-apoB antiserum (BoehringerMannheim) or human anti-albumin antibody (The Binding Site). The samples were incubated on a rocking platform overnight at 4°C. Insoluble Protein A suspension (75 L) was added to each sample and incubated on a rocking platform for 3 hours at 4°C and centrifuged at 14 000 rpm for 2 minutes. Immunoprecipitates were washed 3 times with buffer (PBS containing 1% deoxycholate, 1% Nonidet P-40, 0.1% SDS, 5 mmol/L EDTA). Finally, the immunoprecipitates were prepared for SDS-PAGE by suspending and boiling in 80 L of electrophoresis buffer (10% SDS, 0.5 mol/L Tris, pH 6.8, ␤-mercaptoethanol, 8% glycerol and 0.1% bromophenol blue).
An aliquot of each sample, based on cell protein content, was used for SDS-PAGE (3% to 15% gradient gel) essentially as described by Laemmli. 42 Molecular weight markers (Bio-Rad) were included in each gel. The gels were dried and the radioactivity in each band, corresponding to apoB or albumin, was determined using a phosphoimager system with ImageQuant software (Molecular Dynamics). Alternatively, the gels were treated with Enhance (DuPont), dried, and exposed to Kodak X-Omat AR film. The bands corresponding to apoB and albumin, as visualized by fluorography, were excised from the gel, digested, and the radioactivity determined by scintillation counting. The 2 methods of assessing apoB and albumin radioactivity gave comparable results. The apoB values reported in this study are those determined by volume analysis of the gels scanned using a phosphoimager. This method allows for the selection of the appropriate bands for analysis and correction for background radioactivity. Radioactivity associated with immunoprecipitated apoB from cells 5 minutes after the start of the chase period was used as the maximal rate of incorporation of [
35 S] counts into apoB; all other time points were normalized to these initial counts.
Development of a Multicompartmental Model
The pulse-chase data were analyzed by multicompartmental modelling. A compartmental model of apoB synthesis and secretion was developed using the SAAM II program (SAAM Inst). The model Figure 1 . Diagram of the multicompartmental kinetic model used for analysis of apoB secretion and intracellular degradation. Compartments 1 to 5 and 7 are within the HepG2 cell. Compartment 6 represents apoB in the culture media. Compartments 1 and 2 represent an intracellular pool of tracer and a delay compartment to allow for apoB synthesis after introduction of the tracer, respectively. Compartment 3 represents newly synthesized apoB that may be transferred to compartment 4 and subsequently secreted. From compartment 4, apoB passes through a delay compartment, compartment 5, before secretion into the media, compartment 6. ApoB may be degraded directly from compartment 3 by a rapid degradation pathway. A second, more slowly turning over pool of apoB destined for degradation is represented by compartment 7. The shaded compartments represent the compartments containing apoB radioactivity that were determined experimentally.
was developed using apoB radioactivity data from HepG2 cells and media. Figure 1 shows the compartments of the model and the pathways that connect the compartments. The following is a simplified description of the model development. Initially, an intracellular compartment (compartment 1) was included to represent the dosing compartment (ie, the 35 S-methionine pool). Although the tracer was added to the media, it was assumed that the transport of the tracer into the cells was essentially instantaneous. A second compartment, a delay compartment (compartment 2), was added to represent the time from the initial pulse of radioactivity until cellular immunoprecipitatable apoB radioactivity was detected. Two compartments were then added to represent intracellular apoB radioactivity. Because apoB is progressively lipidated after synthesis, the initial compartment (compartment 3) was designated to represent newly synthesized apoB, and a second compartment (compartment 4) was designated to represent lipidated or partially lipidated apoB destined for secretion. Because most experimental data suggest that apoB degradation results from inadequately lipidated apoB, 11, 43 we initially constructed the model to allow for degradation of apoB entirely from compartment 3 (newly synthesized apoB). Intracellular apoB radioactivity (measured experimentally) was allowed to distribute between these 2 compartments (compartments 3 and 4) in such a manner as to best fit the experimental data. An extracellular compartment (compartment 6) was included to represent media apoB radioactivity, and all of the apoB experimental data derived from media apoB radioactivity was assigned to this compartment. The compartmental model was fit to each data set (cell apoB and media apoB) by taking into account the pulse administration of the 35 S-methionine for 10 minutes. The input of tracer was stopped at 10 minutes to simulate the removal of tracer from the media and was chased with unlabelled methionine. Five minutes after the chase, the first samples were collected for analysis. To optimize the fit, a delay compartment was introduced to represent the time it takes for apoB to appear in the media (compartment 5). A second, more slowly turning over degradation compartment (compartment 7), containing apoB derived from compartment 3 was required to fit the rate of degradation defined by the experimental data. The addition of pathways for apoB secretion directly from compartment 3, or for apoB degradation from compartment 4, were tested, but neither of these pathways were required to fit the model to the experimental data.
RNase Protection Analysis of HepG2 mRNA
A HindIII/PstI fragment of human apoB, cloned into psp72 (Promega) (kindly provided by Dr N. Azrolan, Rockefeller University, NY), a HindIII/XbaI fragment from GAPDH (ATCC) subcloned into pGEM-7Zf (Promega), a PstI/PstI fragment from the human LDL receptor (ATCC) subcloned into pbluescript SKϩ (Stratagene), and a HindIII/PstI fragment of the human HMG-CoA reductase (ATCC) subcloned into pbluescript SKϩ, served as templates to synthesize antisense RNA probes. These riboprobes were then used to measure apoB, GAPDH, LDL receptor, and HMG CoA reductase mRNA in a modification of the RNase protection/solution hybridization assay of Azrolan and Breslow, 44 as described previously. 25 The sample and standard RNAs were assayed in duplicate and hybridization was linear to Ϸ120 pg of cRNA. Within-assay coefficients of variation were Ͻ10%.
Statistical Treatment of Results
All values are presented as meanϮSEM. Tests for statistical significance of differences were compared using unpaired t test for all experiments, with the exception of pulse-chase analysis, which was compared using paired t test. A P valueϽ0.05 was considered significant.
Results
Modulation of ApoB Secretion From HepG2 Cells by ACAT Inhibition
HepG2 cells were incubated with an ACAT inhibitor, CI-1011 or DuP 128, at 10 nmol/L, 1 mol/L, and 10 mol/L concentrations for 24 hours. The media was analyzed for apoB using a noncompetitive sandwich ELISA. Compared with control cells, apoB in the media decreased by 25% (PϽ0.02), 27% (PϽ0.02), and 43% (PϽ0.001) at 10 nmol/L, 1 mol/L, and 10 mol/L of CI-1011, respectively (Table 1) . In contrast, apoB in the media was unchanged by DuP 128 treatment at the same inhibitor concentrations. In preliminary studies CI-1011 and DuP 128 significantly inhibited HepG2 cell cholesterol esterification at concentrations of 10 mol/L. Increasing DuP 128 from 10 mol/L to 20 mol/L did not reveal any effect on apoB accumulation in the media despite a Ͼ90% inhibition of cholesterol esterification (data not shown). Furthermore, increasing the dose of CI-1011 to 20 mol/L did not further enhance the inhibition of apoB secretion. In some experiments, cell viability began to decline at the 20 mol/L dose of both inhibitors. Therefore, a concentration of 10 mol/L was used as the highest dose for the remaining experiments. The ability of these inhibitors to decrease the stimulation of apoB secretion induced by oleic acid treatment was also assessed. HepG2 cells were treated with 0.8 mmol/L oleic acid (complexed to BSA, molar ratio of 5:1) for 24 hours in the presence or absence of CI-1011 (10 mol/L) or DuP 128 (10 mol/L). As shown in Table 1 , oleic acid treatment induced a 2-fold increase in apoB secretion compared with control. Incubation of HepG2 cells with CI-1011 (10 mol/L) decreased apoB secretion by 28.2% (PϽ0.0012) compared with oleic acid-treated controls. In contrast, DuP 128 (10 mol/L) failed to significantly alter apoB secretion in the presence of oleic acid.
Effect on Cell Lipid Mass
To determine the effect of the ACAT inhibitors on the mass of cellular TG, FC, and CE, intracellular lipids were extracted after the 24-hour incubation. CE mass was decreased by 11.9%, 29.6%, and 32% (PϽ0.05) at 10 nmol/L, 1 mol/L, and 10 mol/L CI-1011, respectively (Figure 2A ). DuP 128 decreased CE mass by 7.4%, 40% (PϽ0.011), and 42% (PϽ0.011) at 10 nmol/L, 1 mol/L, and 10 mol/L, respectively (Figure 2A ). There was no significant difference between the 2 inhibitors with respect to their effects on cellular CE mass. FC mass was not significantly changed by either inhibitor at the 3 concentrations examined ( Figure 2B) . A trend for a decrease in TG mass was observed for both inhibitors at 10 nmol/L and 1 mol/L concentrations ( Figure  2C ). This decrease only reached statistical significance for 10 nmol/L DuP 128 (24% reduction, PϽ0.05). At the highest 
Effect on Cell Lipid Biosynthesis and Secretion
Incorporation of [ 14 C] acetic acid or [ 14 C] oleic acid into cellular lipids was measured to determine the effect of CI-1011 and DuP 128 on lipid biosynthetic rates. Cells were treated with the inhibitors at a concentration of 10 mol/L. Incubations with the labeled precursors were carried out from 0 to 5 hours or from 19 to 24 hours after the addition of the inhibitors. This protocol allowed for the measurement of ACAT inhibition over time, and allowed us to determine whether the difference in apoB secretion was caused by a difference in the metabolism or clearance of inhibitor from the hepatocyte, resulting in an attenuation of the effect on cholesterol esterification at later time points. As shown in Table 2 , a significant reduction in the [ 14 C] oleic acid incorporation into CE was found for both inhibitors during the first 5 hours of incubation: a 61.8% decrease for CI-1011 (PϽ0.002) and a 90.1% for DuP 128 (PϽ0.002). During this time, incorporation of [ 14 C] oleic acid into TG was increased 21% (PϽ0.05) by DuP 128 treatment, but was not altered by CI-1011. During the 19-to 24-hour incubation period, the incorporation of oleic acid into CE was decreased by 78.6% for CI-1011 (PϽ0.002) and 85.2% for DuP 128 (PϽ0.002). The inhibition of cholesterol esterification by DuP 128 was greater than that for CI-1011 throughout the 24-hour incubation period, though only significantly greater during the 0-to 5-hour incubation (PϽ0.02). Incorporation of oleic acid into TG from 19 to 24 hours was similar to that seen during the first 5-hour incubation.
The effects of CI-1011 (10 mol/L) and DuP 128 (10 mol/L) on the incorporation of [ 14 C] acetic acid into CE, TC, and PL are presented in Table 3 The effect of CI-1011 (10 mol/L) and DuP 128 (10 mol/L) on the incorporation of oleic acid and acetic acid 
Effect on ApoB Distribution in Secreted Lipoprotein Fractions
To determine the effect of DuP 128 and CI-1011 on the distribution of apoB in secreted lipoproteins, HepG2 cells were incubated with 1 of the inhibitors in the presence of L- [4,5- 3 H] leucine for 24 hours. ApoB from the media lipoprotein fractions VLDL (dϽ1.006 g/mL), IDL (dϭ1.006 to 1.019 g/mL), and LDL (dϭ1.019 to 1.063 g/mL), was isolated and quantitated. The results are shown in Figure 3 . The lipoprotein distribution of apoB in control cells was similar to that reported previously in HepG2 cells that were cultured under similar conditions. 45 Compared with control, DuP 128 (10 mol/L) resulted in a 20% decrease in the recovery of apoB in the VLDL fraction but an increase in the recovery of apoB in the IDL (32% increase) and LDL (29% increase) fractions. The total recovery of apoB in the 3 fractions combined was unchanged (2.6% decrease) compared with control. In contrast, CI-1011 (10 mol/L) resulted in a decreased recovery of apoB in the VLDL (26% decrease), IDL (23% decrease), and LDL (13% decrease) fractions. The total recovery of apoB in the 3 fractions was decreased 25.2%.
Effect of CI-1011 on ApoB Secretion and Intracellular Degradation
To better define the mechanism responsible for reducing the accumulation of apoB in the medium of CI-1011-treated HepG2 cells, pulse-chase studies were conducted. HepG2 cells were preincubated with 10 mol/L CI-1011 for 24 hours, then labeled with Tran [
35 S] methionine for 10 minutes and chased for various periods of time (5 to 120 minutes). Total cellular apoB radioactivity after 5 minutes of chase was not significantly different in CI-1011-treated cells compared with control cells, indicating that apoB synthesis was not affected. Figure 4A and 4C shows the observed data points for apoB secreted into the media and the line of best fit generated by the kinetic model for 2 of 4 separate experiments performed. Inspection of the curves shows that less apoB appears in the media of CI-1011-treated cells. The data for all 4 experiments was analyzed by multicompartmental modelling using SAAM II, and the key kinetic parameters generated from the model are shown in Table 5 . The rate constant k (4, 3) represents the fraction of apoB synthesized that enters the pathway destined for secretion, whereas k(0,3)ϩk (7, 3) represents the fraction of apoB that enters the pathways destined for degradation. The percent of synthesized apoB that is secreted was determined from these rate constants, and was found to be decreased by 42% (Pϭ0.019) in CI-1011-treated cells (4.81% of apoB secreted) compared with control cells (8.30% of apoB secreted). The time from the addition of [ 35 S] methionine until radiolabeled apoB was detected in the media was not affected by CI-1011 (23.4 minutes for CI-1011, compared with 20.8 minutes for control cells). To determine whether the reduced secretion was caused by an enhanced intracellular degradation, the cellular apoB immunoprecipitates were analyzed. Figure 4B and 4D shows the observed data points and the line of best fit generated by the kinetic model for total apoB (media plus intracellular) in 2 of 4 experiments performed. Inspection of the curves shows that the intracellular degradation of apoB is enhanced by CI-1011 treatment. The percent of apoB degraded, as determined by the kinetic analysis, was significantly greater in CI-1011-treated cells (95.2% of apoB degraded) (Table 5 ) compared with control cells (91.7% of apoB degraded, Pϭ0.019). The rate of degradation directly from compartment 3 ( Figure 1 ) was Ϸ2-fold greater than the rate of conversion to compartment 7. The percent of apoB in compartment 3, which was degraded either directly from compartment 3 (71%) or converted to compartment 7 (20%), was unaffected by treatment (data not shown). The recovery of radiolabeled albumin in cell lysates and medium was not significantly different for CI-1011 treatment compared with control at all of the time points (data not shown).
Once secreted into the medium, apoB-containing lipoproteins may be rapidly taken up again by the cells, resulting in a net decrease in medium apoB. To determine the extent of apoB reuptake and whether CI-1011 treatment of HepG2 cells could affect the rate of this uptake, HepG2 cells were pulsed for 10 minutes with Tran [
35 S] label and chased for 60 minutes. The medium was collected and placed onto another set of HepG2 cells that had been incubated in the presence or absence of CI-1011 for 24 hours. The cells were incubated for 60 minutes and the amount of apoB remaining in the medium was determined by immunoprecipitation. There was no difference in apoB radioactivity remaining in the medium from control cells (87.4%) compared with CI-1011 treated cells (84.8%), indicating that the uptake of newly secreted apoBcontaining lipoproteins was low and could not account for the reduction in medium apoB found with CI-1011 treatment.
Effect on ApoB, LDL Receptor, and HMG CoA Reductase mRNA Content
The abundance of specific mRNAs were determined in HepG2 cells treated with CI-1011 (10 mol/L) and DuP 128 (10 mol/L). HepG2 cells were incubated with 1 of the inhibitors for 24 hours and the RNA was extracted and quantitated. As shown in Table 6 , apoB and LDL receptor mRNA levels were not changed by either CI-1011 or DuP 128, compared with control. HMG CoA reductase mRNA significantly decreased by Ϸ39% with CI-1011 and DuP 128, compared with control. GAPDH mRNA levels remained unchanged by CI-1011 or DuP 128 treatment.
Discussion
ACAT inhibitors may have beneficial effects in the treatment of hyperlipidemia and atherosclerosis. These compounds have been shown to prevent foam cell formation in the arterial wall, 46 inhibit cholesterol absorption in the small intestine, 47, 48 and decrease the hepatic secretion of CEs in VLDL. 22 However, the role of cholesterol esterification and the ability of ACAT inhibitors to regulate hepatic apoB secretion is controversial. In particular, the investigation of these processes in HepG2 cells has resulted in conflicting findings. For example, the Sandoz ACAT inhibitor 58-035 has been associated with decreases, 19 no change, 8, 14, 15 or increases 49 in apoB secretion. Also, Kohen Avramoglu et al 20 demonstrated that the increased apoB secretion in CE-loaded HepG2 cells was not inhibited by .
In HepG2 cells, we found that the ACAT inhibitor CI-1011 decreased apoB accumulation in the medium at concentrations ranging from 10 nmol/L to 10 mol/L. In contrast, the ACAT inhibitor DuP 128 did not affect the concentration of apoB in the medium. The hypothesis that ACAT inhibitors reduce the assembly and secretion of apoB-containing lipoproteins by limiting the availability of CE to associate with nascent apoB particles was examined by determining the ability of these inhibitors to reduce cellular CE mass and/or the rate of cholesterol esterification. Based on our finding that CI-1011, but not DuP 128, reduced apoB accumulation in the medium, we expected that CI-1011 would be more effective in reducing cellular CE availability. However, we found that CI-1011 was less effective in decreasing cholesterol esterification and in reducing CE mass, relative to DuP 128, over the 24-hour incubation period. Therefore, the ability of CI-1011 to reduce apoB secretion does not appear to be related to an enhanced ability to reduce CE availability.
Several studies have shown a decrease in apoB secretion after inhibition of HMG-CoA reductase and thus cholesterol synthesis. 19, 21, 24, 39 However, the effect of CI-1011 cannot be explained by changes in FC, as neither inhibitor significantly altered cholesterol synthesis during the initial 5-hour incubation. During the last 5 hours of incubation, both inhibitors caused similar significant reductions in cholesterol synthesis. The reduction in cholesterol synthesis can be explained by a downregulation of HMG-CoA reductase caused by an increase in cellular FC levels secondary to ACAT inhibition.
ApoB secretion has been shown to be regulated by TG 7, 8, [12] [13] [14] [15] and PL 16 availability. CI-1011 did not change either cellular TG mass or synthesis, suggesting that an altered TG availability is not responsible for the effect of this inhibitor on apoB secretion. In this study, DuP 128 (10 mol/L) caused a significant increase in the synthesis of TG. It is possible that this increase in TG may act to compensate for a reduced CE availability, masking an effect on apoB secretion. The increased TG synthesis seen with DuP 128 was modest compared with that usually associated with altered apoB secretion. 13, 50 However, it is possible that DuP 128 may increase a small, but important, pool of TG required for lipoprotein assembly. CI-1011 and DuP 128 did not significantly affect PL synthesis during the 0-to 5-hour incubation. Furthermore, whereas both inhibitors caused small but significant reductions in PL synthesis when measured during the 19-to 24-hour incubation, the reductions were similar for both inhibitors. The reason for the decreased PL synthesis is unknown.
The finding of reduced apoB accumulation in the media of cells incubated with CI-1011, but not DuP 128, is supported by the analysis of the lipoprotein fraction distribution, which shows a reduced accumulation of [ 3 H]-leucine labeled VLDL, IDL, and LDL apoB secreted from the cells incubated with CI-1011. In contrast, DuP 128 caused a shift in the distribution of lipoproteins toward a more dense particle, with no reduction in total apoB accumulation. These results indicate that CI-1011, but not DuP 128, decreased the number of apoB-containing lipoproteins secreted.
To further characterize the regulation of apoB secretion by CI-1011, pulse-chase experiments were carried out. These studies revealed that CI-1011 exerts its effects posttranslationally, as apoB mRNA levels and apoB synthesis were unchanged. The posttranslational regulation by CI-1011 resulted in a decreased secretion of apoB-containing lipoproteins from the HepG2 cells. The decreased secretion was associated with an enhanced intracellular degradation of apoB. The analysis of apoB cellular pulse-chase data by multicompartmental modelling in this study is a novel approach. We have previously used compartmental modelling for in vivo apoB kinetic studies, 23, 25, 33 and have now extended this technique to the analysis of apoB pulse-chase data in HepG2 cells. This approach has allowed us to more precisely define the kinetics of apoB secretion and to identify intracellular pools of apoB with distinct kinetic characteristics. The time from the addition of the 35 S-labeled methionine to the first appearance of labeled apoB in the media was found to be Ϸ23 minutes and was not affected by CI-1011. This time is similar to the estimates previously reported by Bostrom et al. 51 According to the model, apoB radioactivity initially appears in 1 intracellular compartment, designated compartment 3, and subsequently appears in compartment 4. We speculate that compartment 3 represents newly synthesized apoB and that compartment 4 represents lipidated or partially lipidated apoB. ApoB appears to be primarily degraded from compartment 3, a finding that is consistent with the concept that poorly lipidated apoB is targeted for degradation. ApoB is either degraded directly or after transfer to a more slowly turning over degradation compartment (compartment 7). Interestingly, the effect of CI-1011 on degradation is mainly on the rapid, direct degradation pathway, as evidenced by the finding that the rate of degradation directly from compartment 3 is Ϸ2-fold greater than the conversion to compartment 7. Although the intracellular pools of apoB in this study were defined kinetically, it is tempting to speculate that the degradation pathways represent different degradation processes as described by others. 43, [52] [53] [54] [55] It is conceivable that the rapidly turning over degradation pool represents cytoplasmic degradation mediated by the proteasome 43, 52, 53 and that the slowly turning over pool represents apoB degradation within the ER lumen. 54, 55 This study demonstrates the usefulness of multicompartmental modelling for apoB pulse-chase studies. This technique should prove valuable in future studies that seek to explore the mechanisms and characteristics of multiple pathways for apoB intracellular degradation. This is the first report demonstrating that reduced apoB secretion in the presence of an ACAT inhibitor is associated with an increased intracellular degradation of apoB. Graham et al 56 found differing affects on apoB secretion from HepG2 cells by 2 ACAT inhibitors, 447C88 and CL277,082, however the difference was only revealed at inhibitor concentrations of 100 mol/L. Whether the reduction in apoB secretion seen with CL277,082 was caused by alterations in apoB synthesis or intracellular degradation was not determined. More recently, Ooyen at el 49 examined the effect of ACAT inhibition on the intracellular degradation of apoB in HepG2 cells. However, in contrast to our findings, they show a decreased intracellular degradation and increased secretion of apoB using the ACAT inhibitor 58-035. This was thought to be because of enhanced TG synthesis caused by 58-035.
The availability of core lipids such as TG and CE to associate with apoB has been suggested to regulate the rate of apoB translocation, and thus the proportion of apoB secreted. 4, 57 Whether the enhanced intracellular degradation of apoB by CI-1011 is associated with a reduced translocation of apoB across the ER is currently unknown. Additional posttranslational mechanisms may play a role in the regulation of apoB secretion by CI-1011. We have provided evidence that argues against an altered uptake of newly synthesized apoBcontaining lipoproteins. This is supported by an unchanged reuptake of 35 S-labeled apoB from the media, as well as an unaltered LDL receptor mRNA expression. Other possible mechanisms involve the interaction of apoB with various proteases 41, 43, [52] [53] [54] [55] and chaperones 43 during the movement of apoB through the secretory pathway. The microsomal triglyceride transfer protein (MTP) has also been shown to be essential for the secretion of apo B-containing lipoproteins, 58 by mediating the transfer of TG and CE to nascent apoB 59 and possibly by facilitating the translocation of apoB across the ER membrane. 60, 61 It is possible that CI-1011 influences these processes.
The reasons for the observed differences in apoB secretion between CI-1011 and DuP 128 are not clear. The structures of these 2 inhibitors are different. 28, 62 DuP 128 is a lipophilic, noncompetitive ACAT inhibitor with limited oral bioavailability 23 and an in vitro IC 50 of 10 nmol/L for rat liver microsomal ACAT activity. 63, 64 In contrast, CI-1011, is an acyl sulfamate with quite different physiochemical properties compared with the more lipophilic, typical ACAT inhibitors. 28 CI-1011 has a high IC 50 , ranging from 12 mol/L to 60 nmol/L depending on ACAT assay conditions. 28 How these structural differences result in the differential effects on the regulation of apoB secretion are currently unknown.
Previous studies from this laboratory have shown that, in vivo, DuP 128 significantly reduced VLDL apoB secretion into plasma in pigs. 23, 29 CI-1011 significantly inhibited VLDL apoB secretion into plasma to a similar extent, but also decreased LDL apoB secretion. 33 The reason why both ACAT inhibitors decrease apoB secretion in vivo, but not in HepG2 cells, is unknown. The HepG2 cell line has been widely used as a model to study the regulation of apoB secretion. 7, 8, 11, 13, 14, 19, 20, 56 Despite this, HepG2 cells do not assemble typical TG-rich lipoproteins. 65, 66 This is not caused by impaired synthesis of TG in HepG2 cells, but a reduced delivery of newly synthesized TG to a pool available for association with apoB. 50, 65 Although not clearly understood, it is possible that this defect in TG mobilization and lipoprotein assembly renders the HepG2 cell relatively insensitive to regulation of apoB by ACAT inhibition. 8, 14, 15 This study confirms the results found by others, 14, 56 that HepG2 cells may not be an appropriate model to reflect the effect of ACAT inhibition found in vivo. However, the HepG2 cell model has allowed us to determine, using CI-1011, an alternate pathway regulating apoB secretion by mechanism(s) that do not appear to be linked to an ability to alter total cellular CE concentration or esterification rates. Thus, we speculate that, in primary hepatocytes and in vivo, at least 2 intracellular CE pools may regulate apoB secretion and that 1 of these pools may be absent in HepG2 cells, leaving this putative alternate pathway as the primary mechanism for CE-regulated apoB secretion. It is possible that this alternate CE pool is more readily inhibited by CI-1011 compared with DuP 128.
In summary, this study show that ACAT inhibitors with differing properties can exert different effects on the regulation of apoB secretion, which may not be caused by their efficacy in inhibiting cholesterol esterification. Specifically, treatment of HepG2 cells with CI-1011 has revealed potentially novel mechanisms that may contribute to the regulation of apoB. This is the first study to show that reduced apoB secretion in response to ACAT inhibition involves enhanced intracellular degradation of apoB. The nature of these mechanisms, and if they occur in primary hepatocytes or in vivo, requires further investigation.
